ArticleTranslational cancer research2022
The early diagnoses and treatment of anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a patient with breast cancer: a case report.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 3 citations in OpenAlex.
- Movement Disorders Associated With Breast Cancer: A Systematic Review.Annals of Indian Academy of Neurology · 2026Article
- Paraneoplastic cerebellar degeneration from an isolated nodal clear cell carcinoma of suspected gynecologic origin: case report and literature review.Journal of cancer research and clinical oncology · 2026Review
- Breast Cancer with Subacute Progressive Neurological Symptoms due to Anti-Yo Antibody-Associated Paraneoplastic Neurological Syndrome: A Case Report.Surgical case reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Paraneoplastic cerebellar degeneration (PCD) is a relatively rare complication among patients with cancers with nonmetastatic tumor manifestation, including breast cancer. A breast cancer diagnosis is usually made several months (or even years) after the onset of neurological symptoms. Case Description: In this study, we describe the early diagnosis and treatment of PCD in one patient with breast cancer. The patient's first symptom was unsteady gait, followed by dizziness and dysarthria of explosive speech. Subacute progressive ataxia symptoms, weight loss, normal imaging findings, and a lack of evidence of infection combined to lead to clinical diagnosis of PCD, and further confirmed by positron emission tomography-computed tomography (PET-CT), positive anti-Yo antibodies and core needle biopsy. Immunosuppressant therapy consisting of intravenous immunoglobulin (IVIG) and high-dose corticosteroids was effective. The patient underwent modified radical mastectomy and 2 cycles of chemotherapy, and the result suggested that treatment of the primary tumor also improved the neurological symptoms to a certain extent. At 1-year follow-up, there was no evidence of recurrence, and the patient's neurological symptoms were stable. Conclusions: Once PCD was suspected, without clear physical findings or symptoms, PET-CT should be performed for a systemic evaluation for an occult malignancy. Even if the diagnosis and treatment were timely, expectations for prognosis should not be too high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.